Kane-Gill et al. [31] reported the use of urinary TIMP2 × IGFBP7 as an AKI risk screening tool, which resulted in the differential application of various components of the KDIGO bundle for patient management for those with a positive test result. The gene discussed is TIMP2; the disease is acute kidney injury.